연구동향 분석

ORiginal Article : Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine- Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B

( Ji Hyun Kim ) ( Sae Hwan Lee ) ( Hong Soo Kim ) ( Kang Hyug Choi ) ( Soung Won Jeong ) ( Sang Gyune Kim ) ( Jae Young Jang ) ( Young Seok Kim ) ( Boo Sung Kim ) 2015년

논문상세정보
인용/피인용
' ORiginal Article : Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine- Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 기초의학
  • hepatitis b virus
  • lamivudineresistance
  • mutation
  • restriction fragment mass polymorphism
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
756 0

0.0%

' ORiginal Article : Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine- Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B' 의 참고문헌

  • The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
    Ono SK J Clin Invest 107 : 449 ~ 455 [2001]
  • The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment
    Kim HJ Liver Int 32 : 303 ~ 310 [2012]
  • The development of cirrhosis in patients with chronic type B hepatitis: a prospective study
    Liaw YF Hepatology 8 : 493 ~ 496 [1988]
  • Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil
    Yeon JE Gut 55 : 1488 ~ 1495 [2006]
  • Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy
    Kim HJ J Gastroenterol Hepatol 25 : 1374 ~ 1380 [2010]
  • Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
    Lai CL Clin Infect Dis 36 : 687 ~ 696 [2003]
  • Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough
    Lee CH Gastroenterology 130 : 1144 ~ 1152 [2006]
  • Pre-existing YMDD mutants in treatment-naive patients with chronic hepatitis B are not selected during lamivudine therapy
    Lee SH J Med Virol 84 : 217 ~ 222 [2012]
  • Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection
    Zoulim F Antiviral Res 64 : 1 ~ 15 [2004]
  • Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up
    Yatsuji H J Hepatol 48 : 923 ~ 931 [2008]
  • Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
    Hadziyannis SJ Gastroenterology 131 : 1743 ~ 1751 [2006]
  • Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
    van Bömmel F Hepatology 51 : 73 ~ 80 [2010]
  • Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine
    Gaia S J Hepatol 48 : 540 ~ 547 [2008]
  • Lamivudine as initial treatment for chronic hepatitis B in the United States
    Dienstag JL N Engl J Med 341 : 1256 ~ 1263 [1999]
  • Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B
    Wu S Dig Dis Sci 56 : 1207 ~ 1214 [2011]
  • Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy
    Lee YS Hepatology 43 : 1385 ~ 1391 [2006]
  • Hepatitis B virus genetic diversity and mutant
    Yim HJ Korean J Hepatol 14 : 446 ~ 464 [2008]
  • Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern
    Inoue J J Viral Hepat 18 : 206 ~ 215 [2011]
  • Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B
    Kurashige N J Gastroenterol 44 : 601 ~ 607 [2009]
  • Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine
    Hosaka T J Gastroenterol 42 : 368 ~ 374 [2007]
  • Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy
    Leung NW Hepatology 33 : 1527 ~ 1532 [2001]
  • Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment
    Moriconi F J Antimicrob Chemother 60 : 341 ~ 349 [2007]
  • Dynamics of lamivudineresistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy
    Ijaz S J Med Virol 80 : 1160 ~ 1170 [2008]
  • Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments
    Hong SP J Hepatol 40 : 837 ~ 844 [2004]
  • Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients
    Aizawa M J Med Virol 83 : 953 ~ 961 [2011]
  • Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy
    Suzuki F J Med Virol 78 : 1025 ~ 1034 [2006]
  • Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B
    Peters MG Gastroenterology 126 : 91 ~ 101 [2004]
  • Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B
    Rapti I Hepatology d45 : 307 ~ 313 [2007]
  • A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
    Lai CL N Engl J Med 339 : 61 ~ 68 [1998]